StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd (TEVA) stock

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30113% above fair value
$43.24+0.84 (+1.98%)

Close on Nov 11, 2026Market cap $50.39BP/E 72.1Yield –

Teva Pharmaceutical Industries EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Teva Pharmaceutical Industries's EV/EBITDA was 19.5× on Nov 10, 2026, against 10.2× a year earlier. Over the last 5 years it ranged from 3.0× to 236.6×, with a median of 11.9×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 10, 202619.5×+7.5
2025Dec 31, 202511.9×−4.0
2024Dec 31, 202415.9×−183.0
2023Oct 31, 2023198.9×+119.7
2022Dec 30, 202279.2×+76.2
2021Dec 31, 20213.0×−1.7
2020Oct 30, 20204.8×−78.4
2019Apr 30, 201983.2×+75.9
2017Jan 31, 20177.4×−0.5
2016Dec 30, 20167.9×−4.4
2015Dec 31, 201512.3×+2.7
2014Dec 31, 20149.6×−2.2
2013Dec 31, 201311.8×+4.1
2012Dec 31, 20127.8×−1.3
2011Dec 30, 20119.1×−1.9
2010Dec 31, 201010.9×−10.8
2009Dec 31, 200921.7×–

More Teva Pharmaceutical Industries figures

See a number that looks wrong?